Desferoxamine

Desferoxamine

The primary drug used in iron chelation therapy. It aids in counteracting the life-threatening buildup of iron in the body associated with long-term blood transfusions.
Mentioned in: Thalassemia
References in periodicals archive ?
Some of the other agents causing urinary discoloration are Myoglobin, haemoglobin, porphyrins from endogenous sources whereas Rhubarb, black, berries, beet root, artificial food colors and medicines like Rifampin, desferoxamine, Phenolphthalein, Phen-azopyridine etc.
Desferoxamine (DFO)-mediated iron chelation: rationale for a novel approach to therapy for brain cancer.
Cobalt (II) chloride (Co[Cl.sub.2]), desferoxamine (DFO), dimethyloxalylglycine (DMOG), okadaic acid (OA), and glutathione (GSH) were provided by Sigma-Aldrich, USA.
To control the iron levels in their bodies and protect their hearts, doctors at Philippine Children's Medical Center have placed the children on medication: Desferoxamine and Defereprone for both of them and Sumapen for Daisy.
Besides, the proposed scaffold has gradient changing construct, so a vertical gradient porosity along the thickness can be obtained which make it possible to realize spatially control release of desferoxamine (DFO).
The effect of desferoxamine and ferrostatin-1 on the cytotoxicity of artenimol of CCRF-CEM cells was determined by resazurin assays.
(30) Paul Cutler found significant improvement in diabetic control with the use of the iron chelator, desferoxamine, in diabetic patients who also had high ferritin levels.
Conditions predisposing to these infections include diabetes mellitus, hematologic malignancies, organ transplantation, steroid use, acquired immunodeficiency syndrome, treatment with desferoxamine, and iron overload.
Ludolph et al., "Desferoxamine and ethyl-3,4-dihydroxybenzoate protect myocardium by activating NOS and generating mitochondrial ROS," American Journal of Physiology - Heart and Circulatory Physiology, vol.
Acquired factors include bone marrow expansion secondary to ineffective erythropiesis with cortical thinning, hypogonadotropic hypogonadism, hypothyroidism, hypoparathyroidism, diabetes mellitus, direct toxic effects of iron overload on osteoblast number and activity, deleterious effects of desferoxamine on the bone metabolism, the negative impact of chelation therapy on fibroblast proliferation and collagen synthesis, calcium and zinc deficiencies, low vitamin D levels due to aberrant vitamin D-parathyroid hormone axis and reduced physical activity (8-13).
The effects of desferoxamine and ascorbate on oxidative stress in the streptozotocin diabetic rat.
The only drug currently available for the clinical treatment of aluminum intoxication is a natural siderophore desferoxamine B (Hider et al., 1991).